Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while iShares 3 7 Year Treasury Bond ETF trades at $116.7. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | IEI | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Fixed Income |
52-Week High | $28.06 | $120.72 |
52-Week Low | $20.06 | $116.67 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $117.20 with minimal daily movement (+0.08%). Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF focuses exclusively on intermediate-term U.S. Treasury debt, offering lower volatility compared to corporate bond alternatives. Recent dividend payments of $0.36-$0.37 demonstrate consistent income distribution to investors.
The outlook for IEI remains heavily dependent on Federal Reserve policy direction amid ongoing inflation concerns. While Treasury-focused ETFs provide safety during market volatility, rising rate expectations pose headwinds for bond prices. The fund's government debt exposure offers stability but may underperform higher-yielding alternatives in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
